Emerging Role of Biosimilar Epoetins


Recently published in AJKD is a timely perspective by Fishbane et al of the emerging role of biosimilar erythropoiesis-stimulating agents (ESAs) in US nephrology practice. The context is the upcoming expiration of the patent on epoetin alfa (Epogen™/Procrit™) in the US (European patent expired in 2004). A biosimilar is a non-branded copy of a biologic […]

What’s Your Risk of Developing CKD?


There is increasing information about the incidence and prevalence of chronic kidney disease (CKD) in the United States and worldwide, but most adults remain unaware of their current and future risk for developing CKD. Awareness of risks carries the potential to encourage lifestyle, medication, and other interventions to help reduce the risk for CKD progression. […]

The Association of GFR Decline and Clinical Outcomes of CKD

Levey et al AJKD Fig 4

In December 2012, the NKF and FDA jointly co-sponsored a scientific workshop with the objective of  addressing the issues pertaining to use of various GFR definitions and their potential link with commonly designated outcomes and endpoints, e.g., ESKD, elevation in creatinine, death, etc. that are used in the design of clinical trials. As clinical nephrologists, […]

A Model for Funding Young Physician-Researchers in Nephrology

grants folder

Having viable funding opportunities for early career investigators is vital for sustaining a cadre of researchers interested in studying and advancing any field of medicine. This is of particular concern in nephrology where NIH funding for kidney disease research lags behind many other chronic diseases. A recent analysis reported in ASN Kidney News determined that […]

Test Your Knowledge: Lupus Nephritis & Thrombotic Microangiopathy

El-Husseini et al AJKD Fig2b

In the January issue of AJKD, El-Husseini et al describe a case of lupus nephritis-associated thrombotic microangiopathy (TMA) that was successfully treated with eculizumab, a complement inhibitor. The following questions will test your knowledge on lupus nephritis and TMA. Post prepared by Dr. Sairah Sharif, Nephrology Fellow at Winthrop Hospital, Mineola, New York. For a […]

Top 10 eAJKD Posts From 2014

eAJKD Advisory Board member, Dr. Matt Sparks, gathered the top 10 eAJKD posts from 2014 (in reverse order): 10. Kidney Week 2014: New Drug for Hyperkalemia by Dr. Dena Rifkin 9. Welcome to Nephmadness 2014 by Drs. Matt Sparks, Joel Topf, Kenar Jhaveri, Warren Kupin, and Edgar Lerma 8. Recovery time from dialysis session? Does it Matter? by Dr. Veeraish Chauhan […]

Minimal Change Disease Has More Than a Minimal Change on Kidney Function


Minimal change disease has an excellent prognosis in children, with steroid responsiveness and eventual remission even in those with frequent relapses as children progress into adulthood. Even among adults, the prognosis has been described as favorable, with eventual remission rates of over 80% after corticosteroids, albeit with slightly longer courses in some cases. Szeto and […]

Cardiovascular Disease & Mortality in Kidney Transplant Recipients: Is Vitamin K Status the Missing Link?


Matrix Gla is a protein secreted in the arterial media that acts as a calcification inhibitor.  The active form of matrix Gla protein is both carboxylated and phosphorylated.  Carboxylation of matrix Gla protein is dependent on the availability of vitamin K.  Studies have shown higher dp-ucMGP levels in patients with low vitamin K intake and […]

Potassium Busters Have Arrived


Several recent studies of novel potassium binders were recently published in the New England Journal of Medicine (NEJM) and Journal of the American Medical Association (JAMA). Some of the authors of the HARMONIZE trial (Drs. Mikhail Kosiborod, David Packham, Henrik Rasmussen, Alex Yang, and Bhupinder Singh: HMAuthors) discuss their publications about the novel compound ZS-9 […]

Fixed-Dose Hypertonic Saline Protocol for Symptomatic Hyponatremia


The neurologic sequelae of too rapid correction of hyponatremia, such as osmotic demyelination syndrome (ODS), is a feared complication of treatment. Thus, physicians are often hesitant to use 3% hypertonic saline. A recent study published in AJKD describes the use of a fixed protocol of 3% saline for symptomatic hyponatremia. Study authors Drs. Juan Carlos […]


Get every new post delivered to your Inbox.

Join 5,307 other followers